Allianz-backed Koh Young’s brain surgery robot set for US debut by end-August

Koh Young Technology Inc., a South Korean developer of 3D optical inspection devices used in electronics manufacturing, is set to install its brain ...

Celltrion wins Australian approval for eye, bone disease biosimilars

Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...

ABL Bio lands $2.8 billion license-out deal with GSK

ABL Bio Inc., a South Korean biotech company, will license out its proprietary blood-brain barrier shuttle platform, called the Grabody-B, to UK-bas...

Samsung to invest $10 million in US-based C2N Diagnostics

Samsung Group companies will jointly invest $10 million in C2N Diagnostics LLC, a U.S.-based company specializing in blood-based Alzheimer’s d...

Celltrion wins EU approval for autoimmune disease treatment Avtozma

Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...

Koh Young gets OK from FDA for brain surgery robot

Koh Young Technology Inc., a South Korean developer of 3D optical inspection devices used in electronics manufacturing, said on Monday it got 501K...

TALOS dives deeper into brain aneurysm icebergs

 A single neurosurgeon dedicates his or her entire professional career to performing surgeries on an average of fewer than 10,000 patients with...

Celltrion obtains approval of Steqeyma from FDA

South Korea's Celltrion Inc. said on Wednesday it received new drug submission (NDS) approval from the Food and Drug Administration (FDA) for Steq...

Celltrion releases Steqeyma in Europe

South Korea's Celltrion Inc. said on Monday it released Steqeyma (ustekinumab) in Europe, the biosimilar of autoimmune disease treatment Stelara.T...

Celltrion's Zymfentra gets 90% distribution channel in US

South Korean biosimilar maker Celltrion Inc. said on Monday its subcutaneous injection formulation for autoimmune diseases, Zymfentra (infliximab), ...

Near Brain gives hope to millions of stroke patients worldwide

Strokes are the second leading cause of death and the third leading cause of disabilities globally, according to the World Health Organization.To fi...

OpenResearch gets $7.5 mn seed round

OpenResearch, an AI search service founded by former Kakao Brain CEO Kim Il-Doo, said on Thursday that it got a seed round 10 billion won ($7.5 mill...

Kakao to merge dk techin and Kakao Brain

South Korea's Kakao Corp. said on August 23 that its mobile solution development subsidiary dK Techin Corp. will merge with its AI technology affili...

IMBiologics transfers autoimmune disease drug tech to Huadong Pharma

South Korea's antibody-based biotech company IMBiologics announced on Friday that it signed a contract to transfer the technology of its autoimmune ...

Costco sells Celltrion's Yuflyma Low WAC in US

South Korea's Celltrion Inc. announced on Tuesday that its autoimmune disease treatment Yuflyma (Low WAC, active ingredient adalimumab) is now avail...

Celltrion gets approval of Steqeyma in Canada

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Steqeyma, a biosimilar of the autoimmune dise...

Korea’s Koh Young to launch brain surgery robot in US in 2025

Koh Young Technology Inc., a South Korean developer of 3D optical inspection devices used in electronics manufacturing, aims to launch a brain surge...

Celltrion to supply Remsima, Herzuma to Peru

South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and antican...

Samsung Bioepis gets OK to sell Stelara biosimilar in Europe

South Korea's Samsung Bioepis has received approval from the European Commission to sell Pyzchiva, a biosimilar of the autoimmune disease Stelara.&n...

Celltrion releases Remsima SC in Denmark

South Korea's Celltrion Inc. announced on Thursday that it released its autoimmune disease treatment Remsima SC (infliximab) in Denmark. Remsima SC ...

Samsung begins new drug development for rare diseases

Samsung Bioepis Co., a biosimilar development unit of South Korea’s top conglomerate Samsung Group, has begun its new drug development busines...

Reversing age possible in a decade: Harvard Prof. David Sinclair

Humans will be able to control biological age and reverse their age in 10 years with advancements in medical science and live up to around 120, abou...

Celltrion'a autoimmune disease drug Zymfentra makes US debut

South Korean biopharmaceutical giant Celltrion Inc. said on March 17 that it has launched its new autoimmune disease treatment Zymfentra in the US m...

Celltrion ships initial supply of Zymfentra to US

South Korea's Celltrion Inc. announced on Wednesday that it shipped the first supply of its subcutaneous injection type of the autoimmune disease tr...

SK C&C wins Korea’s nod for brain infarct diagnosis AI solution

SK Inc C&C (SK C&C), the information technology service unit of South Korea’s SK Group, said on Thursday it has secured medical device...

Kakao Brain releases medical GenAI tech for free

Kakao Brain, an artificial intelligence (AI) R&D subsidiary of South Korea's Kakao Corp., announced on Tuesday that it has uploaded the Labeler ...

Celltrion to supply Remsima SC, Yuflyma to Norway

South Korea's Celltrion Inc. announced on Wednesday that it will supply its autoimmune disease treatments Remsima SC (infliximab) and Yuflyma, the...

Kakao launches AI-based blood sugar management solution

South Korea’s Kakao Healthcare Corp. has introduced an artificial intelligence-based blood sugar management solution targeting the global digi...

ToolGen gets FDA approval for TGT-001 as ODD

South Korean genome editing developer ToolGen Inc. announced on Monday that its application for orphan drug designation (ODD) of the gene correction...

SK C&C to promote AI healthcare for brain diseases

South Korea's SK C&C announced on Thursday that it signed a strategic business agreement with Neurophet, a cloud-based AI platform for brain ima...